These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1312 related articles for article (PubMed ID: 28851662)

  • 21. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
    Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
    Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma.
    Jiang D; Song Q; Wang H; Huang J; Wang H; Hou J; Li X; Xu Y; Sujie A; Zeng H; Tan L; Hou Y
    Oncotarget; 2017 Jan; 8(5):8315-8329. PubMed ID: 28039448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-small cell lung carcinomas with a minor sarcomatoid component and pleomorphic carcinomas are associated with high expression of programmed death ligand 1.
    Tancoš V; Farkašová A; Kviatkovská Z; Grendár M; Líšková A; Huťka Z; Plank L
    Pathol Res Pract; 2020 Dec; 216(12):153238. PubMed ID: 33059241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Common inherited variants of PDCD1, CD274 and HAVCR2 genes differentially modulate the risk and prognosis of adenocarcinoma and squamous cell carcinoma.
    Moksud N; Wagner M; Pawełczyk K; Porębska I; Muszczyńska-Bernhard B; Kowal A; Wiśniewski A; Kosacka M; Kończak J; Karpiński P; Frydryk D; Andrzejczak A; Karabon L; Kuśnierczyk P; Jasek M
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6381-6390. PubMed ID: 36759392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma.
    Song Z; Yu X; Zhang Y
    Lung Cancer; 2016 Sep; 99():166-71. PubMed ID: 27565935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma.
    Wu S; Shi X; Sun J; Liu Y; Luo Y; Liang Z; Wang J; Zeng X
    Oncotarget; 2017 Mar; 8(10):16421-16429. PubMed ID: 28145884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
    Takada K; Toyokawa G; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
    Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
    Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O
    Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548
    [No Abstract]   [Full Text] [Related]  

  • 30. Aligning digital CD8
    Conde E; Caminoa A; Dominguez C; Calles A; Walter S; Angulo B; Sánchez E; Alonso M; Jimenez L; Madrigal L; Hernando F; Sanz-Ortega J; Jimenez B; Garrido P; Paz-Ares L; de Castro J; Hernandez S; Lopez-Rios F
    Histopathology; 2018 Jan; 72(2):270-284. PubMed ID: 28815764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer.
    Yang CY; Lin MW; Chang YL; Wu CT
    Cancer Biomark; 2017 Dec; 21(1):211-220. PubMed ID: 29036791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
    Takada K; Okamoto T; Shoji F; Shimokawa M; Akamine T; Takamori S; Katsura M; Suzuki Y; Fujishita T; Toyokawa G; Morodomi Y; Okano S; Oda Y; Maehara Y
    J Thorac Oncol; 2016 Nov; 11(11):1879-1890. PubMed ID: 27346415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers.
    Pawelczyk K; Piotrowska A; Ciesielska U; Jablonska K; Gletzel-Plucinska N; Grzegrzolka J; Podhorska-Okolow M; Dziegiel P; Nowinska K
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30769852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
    Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
    Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
    Lozano MD; Abengozar-Muela M; Echeveste JI; Subtil JC; Bertó J; Gúrpide A; Calvo A; de Andrea CE
    Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
    Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
    Takada K; Okamoto T; Toyokawa G; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
    Lung Cancer; 2017 Feb; 104():7-15. PubMed ID: 28213003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High expression of programmed cell death 1 ligand 1 in lung adenocarcinoma is a poor prognostic factor particularly in smokers and wild-type epidermal growth-factor receptor cases.
    Mori S; Motoi N; Ninomiya H; Matsuura Y; Nakao M; Mun M; Okumura S; Nishio M; Morikawa T; Ishikawa Y
    Pathol Int; 2017 Jan; 67(1):37-44. PubMed ID: 27976463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.
    Nomizo T; Ozasa H; Tsuji T; Funazo T; Yasuda Y; Yoshida H; Yagi Y; Sakamori Y; Nagai H; Hirai T; Kim YH
    Sci Rep; 2017 Mar; 7():45124. PubMed ID: 28332580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
    Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
    Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 66.